New RSV shield for infants: Real-World study launches

NCT ID NCT07109297

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study looks at how safe and effective nirsevimab is at preventing severe RSV in babies and young children. About 110 infants and toddlers up to 24 months old will receive the medicine as part of their regular care. Researchers will track side effects and how many children get sick with RSV needing medical attention.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site Number : 3560001

    New Delhi, 110060, India

  • Investigational Site Number : 3560002

    Bengaluru, 560011, India

  • Investigational Site Number : 3560003

    Kolkata, 700017, India

  • Investigational Site Number : 3560004

    Pune, 411007, India

  • Investigational Site Number : 3560006

    Vizianagaram, 535003, India

  • Investigational Site Number : 3560007

    Nagpur, 441108, India

  • Investigational Site Number : 3560008

    Jaipur, 302007, India